HOOK (HOOKIPA Pharma) Growth Rank: 2 (As of Aug. 09, 2026) — 100% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HOOK HOOKIPA Pharma Inc HOOK
50 GF Score
Price $1.15
View Full Analysis

What is HOOKIPA Pharma Growth Rank?

HOOKIPA Pharma HOOK 50 Growth Rank is 2 as of Aug. 09, 2026, which is 100% above its 10-year median of 1.00. GuruFocus rates HOOK with a GF Score™ of 50/100.

HOOKIPA Pharma has the Growth Rank of 2.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

HOOKIPA Pharma Growth Rank Related Terms

HOOK vs COCP, LNAI, CYCN: Growth Rank Comparison

For the Biotechnology subindustry, HOOKIPA Pharma's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

HOOKIPA Pharma Growth Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HOOKIPA Pharma's Growth Rank distribution charts can be found below:

* The bar in red indicates where HOOKIPA Pharma's Growth Rank falls into.


HOOK
50GF Score
HOOKIPA Pharma Inc HOOK
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 2 mean?
HOOKIPA Pharma (HOOK) has a Growth Rank of 2 as of Aug. 09, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on HOOKIPA Pharma and its competitors. This is 100% above median its historical median of 1.00. Over the past decade, HOOKIPA Pharma's Growth Rank has ranged from 1.00 to 2.00.
Is HOOKIPA Pharma's Growth Rank too high?
HOOKIPA Pharma's current Growth Rank of 2 is 100% above median its 10-year median of 1.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 2.00. Overall, HOOKIPA Pharma has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does HOOKIPA Pharma's Growth Rank compare to COCP and LNAI?
HOOKIPA Pharma's Growth Rank of 2 can be compared against companies in the Biotechnology industry. Historically, HOOKIPA Pharma's own Growth Rank has ranged from 1.00 to 2.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Biotechnology company?
A good Growth Rank depends on the Biotechnology industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on HOOKIPA Pharma and its competitors. HOOKIPA Pharma's current Growth Rank is 2, which is 100% above median its own 10-year median of 1.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HOOKIPA Pharma stock overvalued right now?
HOOKIPA Pharma (HOOK) has a current Growth Rank of 2. The current Growth Rank is 2, which is 100% above median its 10-year median of 1.00. HOOKIPA Pharma's overall GF Score™ is 50/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For HOOKIPA Pharma (HOOK), the current Growth Rank is 2 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

HOOKIPA Pharma Business Description

Address 350 Fifth Avenue, 72nd Floor, Suite 7240, New York, NY, USA, 10118
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. The company's product candidates are designed to induce specific, robust and durable CD8+ T cells and antibodies to eliminate cancers and serious infectious diseases. Its pipeline includes biological therapies for oncology, targeting human papillomavirus type 16-positive (HPV16+) cancers, KRAS mutated cancers, and other targets. In addition, It is also focused to develop therapies that are intended to provide functional cures for hepatitis B virus (HBV) and human immunodeficiency virus-1 (HIV-1).
50GF Score

Get the complete analysis for HOOK

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.15
Price